JP2023529001A - 結晶形のラベキシモドを含む経口製剤 - Google Patents

結晶形のラベキシモドを含む経口製剤 Download PDF

Info

Publication number
JP2023529001A
JP2023529001A JP2022576335A JP2022576335A JP2023529001A JP 2023529001 A JP2023529001 A JP 2023529001A JP 2022576335 A JP2022576335 A JP 2022576335A JP 2022576335 A JP2022576335 A JP 2022576335A JP 2023529001 A JP2023529001 A JP 2023529001A
Authority
JP
Japan
Prior art keywords
rabeximod
composition
rheumatoid arthritis
pharmaceutically acceptable
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022576335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529001A5 (https=
Inventor
ビョルクルンド，ウルフ
Original Assignee
シクソン エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シクソン エービー filed Critical シクソン エービー
Publication of JP2023529001A publication Critical patent/JP2023529001A/ja
Publication of JP2023529001A5 publication Critical patent/JP2023529001A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Cosmetics (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2022576335A 2020-06-10 2021-06-10 結晶形のラベキシモドを含む経口製剤 Pending JP2023529001A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20179279.3 2020-06-10
EP20179279 2020-06-10
EP20179277.7 2020-06-10
EP20179239 2020-06-10
EP20179277 2020-06-10
EP20179239.7 2020-06-10
EP20180706 2020-06-18
EP20180706.2 2020-06-18
PCT/EP2021/065705 WO2021250204A1 (en) 2020-06-10 2021-06-10 Oral formulation comprising a crystalline form of rabeximod

Publications (2)

Publication Number Publication Date
JP2023529001A true JP2023529001A (ja) 2023-07-06
JP2023529001A5 JP2023529001A5 (https=) 2024-06-18

Family

ID=76305939

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022576335A Pending JP2023529001A (ja) 2020-06-10 2021-06-10 結晶形のラベキシモドを含む経口製剤
JP2022575226A Pending JP2023529877A (ja) 2020-06-10 2021-06-10 結晶形のラベキシモドの調製方法
JP2022575829A Pending JP2023533662A (ja) 2020-06-10 2021-06-10 関節リウマチの治療におけるラベキシモド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022575226A Pending JP2023529877A (ja) 2020-06-10 2021-06-10 結晶形のラベキシモドの調製方法
JP2022575829A Pending JP2023533662A (ja) 2020-06-10 2021-06-10 関節リウマチの治療におけるラベキシモド

Country Status (8)

Country Link
US (3) US12594274B2 (https=)
EP (3) EP4164650A1 (https=)
JP (3) JP2023529001A (https=)
KR (3) KR20230022880A (https=)
CN (4) CN115768431A (https=)
AU (3) AU2021290174A1 (https=)
CA (3) CA3181629A1 (https=)
WO (3) WO2021250197A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230022880A (ko) 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형
US11643415B1 (en) 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502676A (ja) * 2004-06-17 2008-01-31 オクシーファルマ エイビー アルキル置換されたインドロキノキサリン化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8600260D0 (sv) 1986-01-21 1986-01-21 Lundblad Leif Substituerade indolokinoxaliner
SE504289C2 (sv) * 1994-06-23 1996-12-23 Leif J I Lundblad Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras
JPH08165278A (ja) 1994-12-14 1996-06-25 Kawaken Fine Chem Co Ltd １−置換トリプタミン化合物の製造方法
SE504862C2 (sv) 1994-12-27 1997-05-20 Leif J I Lundblad Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler
DE19516804A1 (de) * 1995-05-08 1996-11-14 Hoechst Ag Isoindolinpigmente auf Basis von Aminochinoxalindionen
US6333327B2 (en) 2000-02-18 2001-12-25 Leif J. I. Lundblad Method for the treatment of Multiple Sclerosis
SE516067C2 (sv) 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
TW200410921A (en) * 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
ATE382623T1 (de) * 2004-06-09 2008-01-15 Hoffmann La Roche Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln
WO2008066151A1 (fr) * 2006-11-30 2008-06-05 Tokyo Institute Of Technology Nouveau dérivé curcumine
CN102115457B (zh) 2011-03-05 2012-11-21 太原理工大学 一种n-乙基咔唑的制备方法
US20150079111A1 (en) * 2012-06-05 2015-03-19 Jonas Axelsson Mechanism, diagnostic, and treatments for complications of renal failure
EA201500942A1 (ru) 2013-03-15 2016-03-31 Виронова Херпес Аб ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
CN105061432B (zh) * 2015-07-16 2017-09-29 河北大学 6H‑吲哚[2,3‑b]喹喔啉衍生物、药物组合物及其制备和应用
TWI842978B (zh) * 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
KR20230022880A (ko) 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형
EP4164649A1 (en) 2020-06-10 2023-04-19 Cyxone AB New use of rabeximod
US11643415B1 (en) * 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502676A (ja) * 2004-06-17 2008-01-31 オクシーファルマ エイビー アルキル置換されたインドロキノキサリン化合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 9, no. 4, JPN6025028054, 2014, pages 163 - 175, ISSN: 0005838820 *
CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. Vol.83, Suppl.1, JPN6025028056, 2008, pages 21 - 42, ISSN: 0005838822 *
EUROPEAN PHARMACEUTICAL REVIEW, vol. 4, JPN6025028053, 2010, ISSN: 0005838819 *
PHARMACEUTICAL RESEARCH, vol. 12, no. 7, JPN6025028055, 1995, pages 945 - 954, ISSN: 0005838821 *
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED ROB 803 WHEN ADDED TO METHOTREXATE, JPN6025028052, 2009, ISSN: 0005838818 *

Also Published As

Publication number Publication date
CA3181637A1 (en) 2021-12-16
KR20230022882A (ko) 2023-02-16
US12594274B2 (en) 2026-04-07
JP2023529877A (ja) 2023-07-12
WO2021250199A1 (en) 2021-12-16
CA3181646A1 (en) 2021-12-16
WO2021250204A1 (en) 2021-12-16
JP2023533662A (ja) 2023-08-04
AU2021289006A1 (en) 2023-02-09
EP4165043A1 (en) 2023-04-19
EP4164616A1 (en) 2023-04-19
CN115698010A (zh) 2023-02-03
CN115768431A (zh) 2023-03-07
US20220133717A1 (en) 2022-05-05
WO2021250197A1 (en) 2021-12-16
US20230227455A1 (en) 2023-07-20
EP4164650A1 (en) 2023-04-19
CA3181629A1 (en) 2021-12-16
AU2021290174A1 (en) 2023-02-09
KR20230022880A (ko) 2023-02-16
US20230227456A1 (en) 2023-07-20
CN115697308A (zh) 2023-02-03
CN120383602A (zh) 2025-07-29
AU2021290173A1 (en) 2023-02-09
KR20230022881A (ko) 2023-02-16

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
AU2017215530B2 (en) Galenic formulations of organic compounds
CN1114879A (zh) 阿齐霉素的给药方法
JP2020063292A (ja) ランタン化合物を含むカプセル製剤及び粉末製剤
US20220323429A1 (en) Pimavanserin for treating neurodegenerative diseases
EP2514422B1 (en) Elution stabilized teneligliptin preparation
AU2024204906A1 (en) Acalabrutinib maleate dosage forms
JP2023529001A (ja) 結晶形のラベキシモドを含む経口製剤
AU2021351536A1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
CN1217721A (zh) 治疗或预防间质膀胱炎的方法
KR20160030093A (ko) 구강 내 붕괴정
US20240100088A1 (en) Novel formulation for treating copper metabolism-associated diseases or disorders
EP4182065B1 (en) Methods of preparing modified dosage forms and related components
WO1996004917A1 (en) Remedy for myotonic dystrophy
JP4866170B2 (ja) 睡眠薬の放出制御医薬組成物及びその製造方法
US20260069569A1 (en) Ebselen containing oral dosage forms
CN107693516A (zh) 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
CA2166427A1 (en) Use of bile acids for preparing medicaments for the treatment of skin diseases
WO2026067737A1 (zh) 三唑类化合物的药物制剂及其制备方法
JP2024533852A (ja) 抗線維化組成物
JP2022536955A (ja) ジクロフェナミド組成物及び使用方法
CZ20002769A3 (cs) Kompozice obsahující celecoxib
JPH01299226A (ja) サラゾスルファピリジン腸溶顆粒

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260414